LSE.co.uk
HomeShare PricesShare ChatFinance NewsSharecast NewsRegulatory NewsShares BookshopFinance ToolsMembers
Latest Share Chat
Finance & Stock Market News
Teva gains UK authorisation for generic version of GSK's migraine drug Imigran
Fri, 4th Jan 2008 11:08
LONDON (Thomson Financial) - The UK medicines regulator the MHRA has announced that it has granted Israeli generics giant Teva approval for a generic version of GlaxoSmithKline's sumatriptan-based migraine drug Imigran.
The approval has been granted under the European Mutual Recognition Procedure, where European member states agree to accept a drug approval application because other member states have already approved it.
However, it is not the first generic version of Imigran that has been approved in the UK -- Dexcel Pharma also received a marketing authorisation for its Sumatriptan Tablets in May 2006.
The new Teva products, Sumatriptan 50mg and 100mg Tablets, have been given a license to be sold as prescription only.
In 2006, Glaxo reported worldwide sales for sumatriptan-based Imigran and Imitrex, one of its top ten pharmaceutical products, of 711 mln stg, up 3 pct on the year before.
ben.deighton@thomson.com
bsd/jrr
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
The approval has been granted under the European Mutual Recognition Procedure, where European member states agree to accept a drug approval application because other member states have already approved it.
However, it is not the first generic version of Imigran that has been approved in the UK -- Dexcel Pharma also received a marketing authorisation for its Sumatriptan Tablets in May 2006.
The new Teva products, Sumatriptan 50mg and 100mg Tablets, have been given a license to be sold as prescription only.
In 2006, Glaxo reported worldwide sales for sumatriptan-based Imigran and Imitrex, one of its top ten pharmaceutical products, of 711 mln stg, up 3 pct on the year before.
ben.deighton@thomson.com
bsd/jrr
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
Member Services
Completely FREE with online Share Chat!
FREE Portfolio and Personalised Watchlist
Completely FREE with online Share Chat!
FREE Portfolio and Personalised Watchlist
